Investing.com - AstraZeneca ADR (NASDAQ: AZN) reported third quarter EPS of $2.08, $1.06 better than the analyst estimate of $1.02. Revenue for the quarter came in at $13.57B versus the consensus estimate of $13.06B.
AstraZeneca ADR's stock price closed at $64.79. It is down -23.24% in the last 3 months and up 1.71% in the last 12 months.
AstraZeneca ADR saw 0 positive EPS revisions and 3 negative EPS revisions in the last 90 days. See AstraZeneca ADR's stock price’s past reactions to earnings here.
According to InvestingPro, AstraZeneca ADR's Financial Health score is "great performance".
Check out AstraZeneca ADR's recent earnings performance, and AstraZeneca ADR's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar